Sargent Investment Group’s Teva Pharmaceuticals TEVA Stock Holding History

Sargent Investment Group’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Hold	0	–	-$54K	–	246
2024 Q4	–	Hold	0	–	–	–	230
2022 Q4	–	Sell	-200,000	Closed	-$11K	–	207
2022 Q3	$11K	Buy	200,000 +100,000	+100%	+$884K	﹤0.01%	184
2022 Q2	$42K	Hold	100,000	–	–	0.01%	182
2022 Q1	$115K	Buy	+100,000	New	+$835K	0.03%	182
2021 Q4	–	Sell	-200,000	Closed	-$59K	–	200
2021 Q3	$59K	Buy	200,000 +100,000	+100%	+$936K	0.01%	187
2021 Q2	$51K	Sell	100,000 -50,000	-33%	-$529K	0.01%	199
2021 Q1	$55K	Buy	+150,000	New	+$1.72M	0.01%	189

Other funds holding TEVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sargent Investment Group's TEVA Position: Q1 2026 in Review

Sargent Investment Group increased its Teva Pharmaceuticals (TEVA) stake by 1.3% in Q1 2026, buying an estimated $53.4K and bringing the position to 130,330 shares worth $3.93M. The position accounts for 0.52% of the portfolio, ranked #48.

Sargent Investment Group first reported a position in TEVA in Q2 2021 and has held it in 19 quarters since. The position peaked at $4.02M in Q4 2025. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

Sargent Investment Group held 130,330 shares of Teva Pharmaceuticals worth $3.93M as of Q1 2026.
Sargent Investment Group bought 1,660 Teva Pharmaceuticals shares in Q1 2026, an estimated $53.4K.
Teva Pharmaceuticals made up 0.52% of Sargent Investment Group's portfolio in Q1 2026, its #48 holding.
Sargent Investment Group first reported a position in Teva Pharmaceuticals in Q2 2021 and has held it in 19 quarters since.
Sargent Investment Group's Teva Pharmaceuticals position peaked at $4.02M in Q4 2025.
651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Sargent Investment Group's 13F filing for Q1 2026, filed 11 May 2026.